SUPN Supernus Pharmaceuticals Inc.

35.76
+0.16  (+0%)
Previous Close 35.6
Open 35.4
Price To Book 4.43
Market Cap 1868710785
Shares 52,257,013
Volume 1,020,081
Short Ratio
Av. Daily Volume 610,263

SEC filingsSee all SEC filings

  1. 8-K - Current report 181227032
  2. CT ORDER - Confidential treatment order 181210150
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171666
  4. 8-K - Current report 181170209
  5. 8-K - Current report 181163747

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 22, 2017.
Oxtellar
Epilepsy
Phase 3 data from two of its trials in children released December 6, 2018 met primary endpoints but with concerns regarding effect size vs competition. Data from first adolescent trial due by the end of December 2018 while data from the second trial are due 1Q 2019.
SPN-812
ADHD
Phase 3 data due mid-2019
SPN-810
Impulsive Aggression in ADHD
Approved Aug 19, 2013.
Trokendi
Epilepsy
Tentative approval August 19 2016, subject to the pediatric exclusivity which expires March 28, 2017. Final approval announced April 6, 2017.
Trokendi
Migraine
FDA approval announced December 14, 2018 to expand label to include monotherapy treatment.
Oxtellar XR
Epilepsy

Latest News

  1. Supernus Announces FDA Approval of sNDA to Expand Oxtellar XR® Label to Include Monotherapy
  2. 3 Top Biotech Stocks to Buy in December
  3. This Index Of Leading Stocks Falls Into A Bear Market As Boeing Stings Dow Jones
  4. Supernus Pharma's ADHD treatment fails to impress; shares fall
  5. Here's Why Supernus Pharmaceuticals Is Sinking Today
  6. See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
  7. Consolidated Research: 2018 Summary Expectations for TD Ameritrade Holding, Supernus Pharmaceuticals, Akcea Therapeutics, Dell Technologies, iRobot, and Pegasystems — Fundamental Analysis, Key Performance Indications
  8. The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering
  9. Supernus Pharma's ADHD treatment succeeds in two late-stage studies
  10. Supernus Announces Positive Results from Two Phase III Studies For SPN-812 in Children with ADHD
  11. Supernus Schedules Conference Call to Present Topline Results of Two Phase III Studies for SPN-812 in Children with ADHD
  12. Today's Research Reports on Trending Tickers: Incyte and Supernus Pharmaceuticals
  13. Stock Market Stages Bullish Reversal To Cap Week With Big Gains
  14. Today's Research Reports on Trending Tickers: Heron Therapeutics and Supernus Pharmaceuticals
  15. What Should Investors Know About Supernus Pharmaceuticals Inc’s (NASDAQ:SUPN) Future?
  16. 5 Sizzling Small-Cap Stocks to Buy Today
  17. Supernus to Present at Three November Healthcare Conferences
  18. Edited Transcript of SUPN earnings conference call or presentation 7-Nov-18 2:00pm GMT

SEC Filings

  1. 8-K - Current report 181227032
  2. CT ORDER - Confidential treatment order 181210150
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171666
  4. 8-K - Current report 181170209
  5. 8-K - Current report 181163747
  6. 8-K - Current report 181139485
  7. 8-K - Current report 181080173
  8. 8-K - Current report 181075424
  9. 8-K - Current report 181058748
  10. 8-K - Current report 181053039